Welcome to our dedicated page for Angle Plc Surrey news (Ticker: ANPCF), a resource for investors and traders seeking the latest updates and insights on Angle Plc Surrey stock.
About ANGLE Plc
ANGLE Plc (OTCQX: ANPCF), headquartered in Guildford, Surrey, is a pioneering biotechnology company specializing in liquid biopsy solutions for oncology research, drug development, and clinical diagnostics. The company’s flagship product, the Parsortix® PC1 System, is a patented and FDA-cleared technology designed to isolate and harvest circulating tumor cells (CTCs) from patient blood samples. This innovative system overcomes the limitations of traditional tissue biopsies by enabling minimally invasive, repeatable, and dynamic monitoring of cancer biomarkers. ANGLE’s technology provides researchers and clinicians with a comprehensive platform for whole-cell imaging, proteomic analysis, and genomic and transcriptomic profiling.
Core Business Areas
ANGLE operates across two primary business segments:
- Diagnostic Products: The Parsortix system and its associated consumables, such as the Portrait+ CTC Staining Kit and CellKeep™ slide, offer robust solutions for isolating and analyzing CTCs. These products are designed for use in translational research, biomarker discovery, and clinical oncology.
- Clinical Services: Through its GCLP-compliant laboratories, ANGLE provides custom assay development, clinical trial testing, and pharma services. These offerings cater to pharmaceutical companies seeking to integrate liquid biopsy technologies into drug development and precision medicine initiatives.
Market Position and Competitive Landscape
ANGLE Plc is a recognized leader in the liquid biopsy market, a rapidly growing sector driven by advancements in precision medicine and the increasing demand for non-invasive diagnostic tools. The company’s unique, marker-independent CTC harvesting technology sets it apart from competitors focused on circulating tumor DNA (ctDNA) analysis. With over 90 peer-reviewed publications validating the Parsortix system, ANGLE has established itself as a trusted partner for academic researchers, pharmaceutical companies, and clinicians. Key differentiators include its ability to capture a diverse range of CTC phenotypes, including mesenchymal cells and CTC clusters, which are critical for understanding cancer progression and metastasis.
Innovation and Intellectual Property
ANGLE’s commitment to innovation is reflected in its robust intellectual property portfolio, which includes patents for technologies like the CellKeep™ slide. This device significantly reduces CTC loss during microscopy-based analysis, enhancing assay sensitivity and preserving cell morphology. The company’s collaboration with NuProbe USA, Inc. to integrate next-generation sequencing (NGS) assays further underscores its focus on expanding the utility of its liquid biopsy platform. By combining CTC and ctDNA analysis, ANGLE aims to provide unparalleled insights into tumor evolution, drug resistance, and treatment response.
Strategic Vision
ANGLE Plc is at the forefront of enabling biomarker-guided precision medicine. Its solutions empower clinicians to monitor disease progression and treatment efficacy in real-time, paving the way for personalized cancer therapies. The company’s strategic partnerships with leading pharmaceutical firms and its participation in high-profile conferences highlight its role as a catalyst for innovation in oncology diagnostics.
Why ANGLE Matters
By addressing the unmet need for minimally invasive, repeatable, and dynamic cancer diagnostics, ANGLE Plc is transforming the way cancer is studied and treated. Its technology not only enhances the sensitivity and specificity of biomarker analysis but also opens new avenues for translational research and clinical applications. As the demand for precision medicine continues to grow, ANGLE’s solutions are poised to play a pivotal role in shaping the future of oncology.
ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.
The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.
The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.
ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.
The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.
ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.
ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.
The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with NuProbe USA, Inc. for the use of their proprietary pan-cancer next generation sequencing (NGS) panel. The agreement grants ANGLE an option for an exclusive global license to the NGS panel outside of China for analyzing circulating tumor cells (CTCs) and dual analysis of CTCs and circulating tumor DNA (ctDNA).
The NGS panel enables highly sensitive detection of over 6,500 DNA mutations in 61 clinically relevant genes. It has been validated on the Illumina sequencer and aligns with key drug targets under development by large pharma. This agreement aims to accelerate ANGLE's commercialization of its first pan-cancer molecular sequencing assay, with immediate applicability to pharma services customers and translational researchers using the Parsortix® system.
A pilot study conducted by ANGLE demonstrated that more mutations were identified exclusively in CTCs compared to ctDNA alone in breast, lung, and ovarian cancer patients, highlighting the potential value of profiling CTCs in addition to ctDNA.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.
An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.
ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.
On July 12, 2024, Angle PLC, a UK-based company, announced a significant change in its major shareholdings. Dermot Keane, based in London, UK, has crossed the 5% threshold, increasing his voting rights from 4.90% to 8.09%, amounting to 26,110,422 voting rights. The notification was triggered by an acquisition of voting rights, with the official threshold crossing occurring on June 5, 2024. This information was published through the London Stock Exchange's Regulatory News Service (RNS), approved by the Financial Conduct Authority (FCA). No other financial instruments or changes in voting rights breakdown were reported.
ANGLE plc, a leader in liquid biopsy solutions for CTCs, announced the posting of its 2023 Annual Report and Financial Statements. The report, covering the year ending December 31, 2023, is available on the company's website. Shareholders have been invited to the Annual General Meeting (AGM) scheduled for July 11, 2024, at the Surrey Technology Centre. The AGM will include a business update following formal proceedings. This announcement is significant for stakeholders tracking corporate governance and financial performance of ANGLE plc.
FAQ
What is the current stock price of Angle Plc Surrey (ANPCF)?
What is the market cap of Angle Plc Surrey (ANPCF)?
What does ANGLE Plc specialize in?
What is the Parsortix system?
Who are ANGLE’s primary customers?
How does ANGLE differentiate itself from competitors?
What are ANGLE’s key innovations?
What is the significance of ANGLE’s FDA clearance?
What industries does ANGLE operate in?
What are the potential applications of ANGLE’s technology?
